SG11202106168VA - Insulin analogs having reduced insulin receptor binding affinity - Google Patents
Insulin analogs having reduced insulin receptor binding affinityInfo
- Publication number
- SG11202106168VA SG11202106168VA SG11202106168VA SG11202106168VA SG11202106168VA SG 11202106168V A SG11202106168V A SG 11202106168VA SG 11202106168V A SG11202106168V A SG 11202106168VA SG 11202106168V A SG11202106168V A SG 11202106168VA SG 11202106168V A SG11202106168V A SG 11202106168VA
- Authority
- SG
- Singapore
- Prior art keywords
- insulin
- binding affinity
- receptor binding
- reduced
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306657 | 2018-12-11 | ||
| EP18306659 | 2018-12-11 | ||
| EP18306658 | 2018-12-11 | ||
| PCT/EP2019/084427 WO2020120477A1 (en) | 2018-12-11 | 2019-12-10 | Insulin analogs having reduced insulin receptor binding affinity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106168VA true SG11202106168VA (en) | 2021-07-29 |
Family
ID=68806785
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106167XA SG11202106167XA (en) | 2018-12-11 | 2019-12-10 | Insulin conjugates |
| SG11202106168VA SG11202106168VA (en) | 2018-12-11 | 2019-12-10 | Insulin analogs having reduced insulin receptor binding affinity |
| SG11202106166TA SG11202106166TA (en) | 2018-12-11 | 2019-12-10 | Peptide binder |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106167XA SG11202106167XA (en) | 2018-12-11 | 2019-12-10 | Insulin conjugates |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106166TA SG11202106166TA (en) | 2018-12-11 | 2019-12-10 | Peptide binder |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11098102B2 (en) |
| EP (3) | EP3893934A1 (en) |
| JP (3) | JP2022513776A (en) |
| KR (3) | KR20210102346A (en) |
| CN (3) | CN113423691A (en) |
| AU (3) | AU2019398402A1 (en) |
| BR (3) | BR112021011099A2 (en) |
| CA (3) | CA3122636A1 (en) |
| CO (1) | CO2021007453A2 (en) |
| IL (3) | IL283803A (en) |
| MX (3) | MX2021006970A (en) |
| PH (1) | PH12021551339A1 (en) |
| SG (3) | SG11202106167XA (en) |
| TW (3) | TW202039438A (en) |
| WO (3) | WO2020120479A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112876388B (en) * | 2021-01-14 | 2023-03-31 | 山东大学 | GPR120 agonist and preparation method and application thereof |
| CN116162147B (en) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | Long-acting insulin analogue |
| CN114230451A (en) * | 2021-12-29 | 2022-03-25 | 上海药坦药物研究开发有限公司 | Preparation method of halogenated acid compound |
| WO2023144277A1 (en) * | 2022-01-26 | 2023-08-03 | Sanofi | Insulin conjugates |
| WO2023247640A1 (en) | 2022-06-23 | 2023-12-28 | Sanofi | Single chain insulins and fc conjugates thereof |
| CN115850385B (en) * | 2022-07-04 | 2023-08-11 | 北京惠之衡生物科技有限公司 | Expression-promoting peptide and application thereof |
| WO2024051787A1 (en) * | 2022-09-09 | 2024-03-14 | 北京惠之衡生物科技有限公司 | Long-acting acylated insulin derivative and use thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU682061B2 (en) | 1993-09-17 | 1997-09-18 | Novo Nordisk A/S | Acylated insulin |
| PL183698B1 (en) | 1995-03-17 | 2002-06-28 | Novo Nordisk As | Derivatives of insulin |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| CA2306877A1 (en) | 1997-10-24 | 1999-05-06 | Eli Lilly And Company | Insoluble insulin compositions |
| KR20070029247A (en) | 2004-07-08 | 2007-03-13 | 노보 노르디스크 에이/에스 | Polypeptide protracting tags |
| EP1846447B1 (en) | 2005-02-02 | 2013-08-21 | Novo Nordisk A/S | Insulin derivatives |
| JP4933455B2 (en) | 2005-02-02 | 2012-05-16 | ノヴォ ノルディスク アー／エス | New insulin derivatives |
| WO2007020256A1 (en) | 2005-08-16 | 2007-02-22 | Novo Nordisk A/S | Method for making mature insulin polypeptides |
| JP5202338B2 (en) | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー／エス | New insulin derivatives |
| WO2007104736A2 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| WO2007128815A1 (en) | 2006-05-09 | 2007-11-15 | Novo Nordisk A/S | Insulin derivative |
| AU2007247109B2 (en) | 2006-05-09 | 2012-03-15 | Novo Nordisk A/S | Insulin derivative |
| CN101573133B (en) | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | PEGylated, extended insulins |
| ES2601839T3 (en) | 2006-09-22 | 2017-02-16 | Novo Nordisk A/S | Protease resistant insulin analogs |
| WO2008049711A1 (en) | 2006-10-27 | 2008-05-02 | Novo Nordisk A/S | Peptide extended insulins |
| GB0621973D0 (en) * | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| JP5688969B2 (en) | 2007-07-16 | 2015-03-25 | ノボ・ノルデイスク・エー／エス | Pegylated insulin analogues are stable against proteases |
| CA2695970A1 (en) | 2007-08-15 | 2009-02-19 | Novo Nordisk A\S | Insulin analogues with an acyl and aklylene glycol moiety |
| US8962794B2 (en) | 2007-08-15 | 2015-02-24 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| JP5547083B2 (en) | 2007-11-20 | 2014-07-09 | アンブルックス，インコーポレイテッド | Modified insulin polypeptides and their use |
| WO2009112583A2 (en) * | 2008-03-14 | 2009-09-17 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
| MX2010009850A (en) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Protease stabilized, acylated insulin analogues. |
| CN102065903B (en) | 2008-04-01 | 2015-02-18 | 诺沃-诺迪斯克有限公司 | Insulin albumin conjugates |
| PL219335B1 (en) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | New slow-release insulin analogues |
| CN102202683A (en) | 2008-10-30 | 2011-09-28 | 诺沃-诺迪斯克有限公司 | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| EP2376531A1 (en) | 2008-12-09 | 2011-10-19 | Novo Nordisk A/S | Novel insulin analogues |
| CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
| CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| JP5969461B2 (en) * | 2010-04-27 | 2016-08-17 | ジーランド ファーマ アクティーゼルスカブ | Peptide complex of GLP-1 receptor agonist and gastrin and use thereof |
| CN107029212A (en) | 2010-05-10 | 2017-08-11 | 诺沃—诺迪斯克有限公司 | Method for preparing zinc insulin compound |
| JP5912112B2 (en) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Amide insulin prodrug |
| JP2013540771A (en) | 2010-10-15 | 2013-11-07 | ノヴォ ノルディスク アー／エス | Novel N-terminally modified insulin derivative |
| JP6058646B2 (en) | 2011-06-15 | 2017-01-11 | ノヴォ ノルディスク アー／エス | Multi-substituted insulin |
| CN104011070A (en) | 2011-12-15 | 2014-08-27 | 爱德迪安（北京）生物技术有限公司 | Compound And Composition Having Hypoglycemic Effect And Use Thereof |
| CA2858253A1 (en) | 2011-12-15 | 2013-06-20 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Human insulin analogue and acylated derivative thereof |
| US20140357838A1 (en) | 2011-12-21 | 2014-12-04 | Novo Nordisk A/S | N-Terminally Modified Insulin Derivatives |
| EP2869830B1 (en) | 2012-07-09 | 2016-10-12 | Novo Nordisk A/S | Novel use of insulin derivatives |
| EP2914620B1 (en) | 2012-11-05 | 2018-08-08 | Case Western Reserve University | Long-acting single-chain insulin analogues |
| CN114989289A (en) | 2013-02-26 | 2022-09-02 | 韩美药品株式会社 | Novel insulin analogues and uses thereof |
| KR20150131213A (en) | 2013-03-14 | 2015-11-24 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Insulin-incretin conjugates |
| WO2014147141A1 (en) | 2013-03-20 | 2014-09-25 | Novo Nordisk A/S | Insulin dosing regimen |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| EP3004156A1 (en) | 2013-06-07 | 2016-04-13 | Novo Nordisk A/S | Method for making mature insulin polypeptides |
| WO2015016293A1 (en) * | 2013-08-02 | 2015-02-05 | 国立大学法人 富山大学 | (benzenesulfonylamino)benzamide derivative, and ship2 inhibitor containing same as active ingredient |
| MA39301A1 (en) | 2014-01-20 | 2018-01-31 | Hanmi Pharmaceutical Co Ltd | Long-acting insulin and associated use |
| AR099569A1 (en) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE |
| AR100639A1 (en) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | COMPOSITION TO TREAT DIABETES THAT INCLUDES CONJUGATES OF PROLONGED INSULIN ANALOGS AND CONJUGATES OF PROLONGED INSULINOTROPIC PEPTIDES |
| KR20160001391A (en) | 2014-06-27 | 2016-01-06 | 한미약품 주식회사 | Novel long acting insulin analog and use thereof |
| WO2016001185A1 (en) | 2014-07-02 | 2016-01-07 | Novo Nordisk A/S | Dosage regimen for the treatment of diabetes |
| KR20160007295A (en) | 2014-07-11 | 2016-01-20 | 한미약품 주식회사 | Insulin analog |
| US20180000742A1 (en) | 2015-01-29 | 2018-01-04 | Novo Nordisk A/S | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating |
| WO2016172269A2 (en) | 2015-04-20 | 2016-10-27 | University Of Utah Research Foundation | Insulin analogs having shortened b chain peptides and associated methods |
| JP2018531901A (en) | 2015-08-25 | 2018-11-01 | ノヴォ ノルディスク アー／エス | Novel insulin derivatives and their medical use |
| CN108368163A (en) | 2015-08-25 | 2018-08-03 | 诺和诺德股份有限公司 | Novel insulin derivates and its medical usage |
| DK3341044T3 (en) | 2015-08-25 | 2020-02-17 | Novo Nordisk As | MEDICAL INJECTION DEVICE WITH A CLEANING ROOM |
| PL239062B1 (en) | 2016-01-22 | 2021-11-02 | Inst Biotechnologii I Antybiotykow | Method for producing insulin and its derivatives and the hybrid peptide used in this method |
| EP3495384A4 (en) | 2016-08-02 | 2020-02-26 | Jiangsu Hengrui Medicine Co., Ltd. | Acylated derivative of human insulin or analogue thereof |
| JP7158378B2 (en) * | 2016-09-23 | 2022-10-21 | ハンミ ファーマシューティカル カンパニー リミテッド | Insulin analogue with reduced binding force with insulin receptor and use thereof |
| JP7286160B2 (en) | 2016-11-21 | 2023-06-05 | ケース ウェスタン リザーブ ユニバーシティ | A fast-acting insulin analogue with enhanced stability |
| AU2017378102B2 (en) | 2016-12-16 | 2022-10-13 | Novo Nordisk A/S | Insulin containing pharmaceutical compositions |
| AU2018215840A1 (en) | 2017-02-03 | 2019-08-01 | Hanmi Pharm. Co., Ltd. | Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof |
| US11752216B2 (en) | 2017-03-23 | 2023-09-12 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
| JOP20190273A1 (en) | 2017-05-26 | 2019-11-24 | Lilly Co Eli | Acylated insulin compound |
| KR20190036956A (en) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | A long acting single chain insulin analog and a conjugate thereof |
| WO2019125879A2 (en) | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Conjugate based systems for controlled insulin delivery |
-
2019
- 2019-12-10 WO PCT/EP2019/084433 patent/WO2020120479A1/en active Application Filing
- 2019-12-10 BR BR112021011099-2A patent/BR112021011099A2/en unknown
- 2019-12-10 AU AU2019398402A patent/AU2019398402A1/en active Pending
- 2019-12-10 CN CN201980091302.5A patent/CN113423691A/en active Pending
- 2019-12-10 BR BR112021011050-0A patent/BR112021011050A2/en unknown
- 2019-12-10 US US16/709,208 patent/US11098102B2/en active Active
- 2019-12-10 AU AU2019398579A patent/AU2019398579A1/en active Pending
- 2019-12-10 BR BR112021011156-5A patent/BR112021011156A2/en unknown
- 2019-12-10 JP JP2021533149A patent/JP2022513776A/en active Pending
- 2019-12-10 CA CA3122636A patent/CA3122636A1/en active Pending
- 2019-12-10 TW TW108145067A patent/TW202039438A/en unknown
- 2019-12-10 SG SG11202106167XA patent/SG11202106167XA/en unknown
- 2019-12-10 AU AU2019398658A patent/AU2019398658A1/en active Pending
- 2019-12-10 KR KR1020217021395A patent/KR20210102346A/en unknown
- 2019-12-10 MX MX2021006970A patent/MX2021006970A/en unknown
- 2019-12-10 TW TW108145065A patent/TW202039437A/en unknown
- 2019-12-10 WO PCT/EP2019/084400 patent/WO2020120463A1/en unknown
- 2019-12-10 SG SG11202106168VA patent/SG11202106168VA/en unknown
- 2019-12-10 KR KR1020217021394A patent/KR20210102345A/en not_active Application Discontinuation
- 2019-12-10 JP JP2021533153A patent/JP2022511567A/en active Pending
- 2019-12-10 CN CN201980091301.0A patent/CN113395982A/en active Pending
- 2019-12-10 CN CN201980091275.1A patent/CN113396157A/en active Pending
- 2019-12-10 EP EP19816338.8A patent/EP3893934A1/en active Pending
- 2019-12-10 MX MX2021006969A patent/MX2021006969A/en unknown
- 2019-12-10 WO PCT/EP2019/084427 patent/WO2020120477A1/en unknown
- 2019-12-10 KR KR1020217021396A patent/KR20210102347A/en unknown
- 2019-12-10 JP JP2021533148A patent/JP2022513775A/en active Pending
- 2019-12-10 MX MX2021006972A patent/MX2021006972A/en unknown
- 2019-12-10 TW TW108145066A patent/TW202039539A/en unknown
- 2019-12-10 EP EP19816708.2A patent/EP3894391A1/en active Pending
- 2019-12-10 CA CA3122632A patent/CA3122632A1/en active Pending
- 2019-12-10 EP EP19816341.2A patent/EP3894435A1/en active Pending
- 2019-12-10 CA CA3122637A patent/CA3122637A1/en active Pending
- 2019-12-10 SG SG11202106166TA patent/SG11202106166TA/en unknown
-
2021
- 2021-05-25 US US17/329,558 patent/US20220048968A1/en active Pending
- 2021-06-07 PH PH12021551339A patent/PH12021551339A1/en unknown
- 2021-06-08 IL IL283803A patent/IL283803A/en unknown
- 2021-06-08 CO CONC2021/0007453A patent/CO2021007453A2/en unknown
- 2021-06-08 IL IL283800A patent/IL283800A/en unknown
- 2021-06-08 IL IL283801A patent/IL283801A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283800A (en) | Insulin analogs having reduced insulin receptor binding affinity | |
| IL280670A (en) | Il-2 receptor binding compounds | |
| ZA201704797B (en) | Agonistic tnf receptor binding agents | |
| ZA201906358B (en) | Improved antigen binding receptors | |
| GB201802201D0 (en) | Binding agents | |
| GB2551945B (en) | Novel GLP-1 receptor agonist peptides | |
| EP3820474A4 (en) | Adenosine receptor binding compounds | |
| EP3623163A4 (en) | Saddle stitch binding system | |
| GB201911187D0 (en) | Receptor | |
| IL304317A (en) | Tgf-beta-rii binding proteins | |
| IL269731A (en) | Signature-hash for multi-sequence files | |
| IL269477A (en) | Il-1r-i binding polypeptide | |
| CA195748S (en) | Binder mechanism | |
| GB201810318D0 (en) | Peptide ligrands for binding to PSMA | |
| GB201801842D0 (en) | Affinity chromatography | |
| IL272798A (en) | Agonistic tnf receptor binding agents | |
| GB201901704D0 (en) | Binding polypeptides | |
| GB201919286D0 (en) | Binding proteins | |
| GB201912657D0 (en) | Binding members | |
| GB201908865D0 (en) | Spine binder | |
| GB201910899D0 (en) | Binding members | |
| GB201908993D0 (en) | Saddle | |
| GB201801959D0 (en) | Binding polypeptides | |
| GB201802995D0 (en) | File serving | |
| GB201806135D0 (en) | Saddle pad |